Pentasaccharide Org31540/SR90107A clinical trials update: lessons for practice

Area of Science:

• Pharmacology
• Thrombosis Research
• Orthopedic Surgery

Background:

• Patients undergoing orthopedic surgery face a high risk of venous thromboembolism (VTE).
• Current prophylactic treatments like low-molecular-weight heparin (LMWH) and warfarin have limitations.
• There is a need for alternative antithrombotic agents with improved efficacy and safety profiles.

Purpose of the Study:

• To investigate the efficacy and safety of a new synthetic pentasaccharide, Org31540/SR90107A, a selective Factor Xa inhibitor.
• To determine the optimal dose of Org31540/SR90107A for VTE prevention in patients undergoing total hip replacement.
• To compare Org31540/SR90107A with enoxaparin, a standard LMWH prophylaxis.

Main Methods:

• A phase II, double-blind, dose-ranging study involving 933 patients undergoing elective total hip replacement.
• Random assignment to five Org31540/SR90107A dose groups (0.75–8 mg/d) or enoxaparin (30 mg every 12 hours).
• Treatment initiated post-surgery for 5–10 days, with outcomes assessed for deep vein thrombosis (DVT) and major bleeding.

Main Results:

• The study demonstrated a dose-related improvement in efficacy and safety for Org31540/SR90107A compared to enoxaparin.
• The 6.0- and 8.0-mg/d groups were discontinued early due to safety considerations.
• A dose of 2.5 mg once daily was selected as optimal for subsequent phase III trials.

Conclusions:

• Org31540/SR90107A is a novel synthetic antithrombotic agent.
• It exhibits significant dose-dependent efficacy and safety in VTE prophylaxis following orthopedic surgery.
• The findings support its potential as an alternative prophylactic agent in this patient population.